A novel noninvasive index for nonalcoholic steatohepatitis: a pilot study

作者：Polyzos Stergios A^*; Kountouras Jannis; Slavakis Aristeidis; Zafeiriadou Efthimia; Patsiaoura Kalliopi; Katsiki Evangelia; Zavos Christos; Papatheodorou Athanasios; Terpos Evangelos

来源：Biomarkers, 2013, 18(7): 607-613.

DOI：10.3109/1354750X.2013.838305

• Erythrocyte sedimentation rate
• homocysteine
• insulin resistance
• metabolic syndrome
• nonalcoholic fatty liver disease
• serum glutamic oxaloacetic transaminase

Objective: The potential development of a noninvasive marker predicting nonalcoholic steatohepatitis (NASH). %26lt;br%26gt;Methods: Thirty patients with biopsy-proven nonalcoholic fatty liver disease were evaluated by numerous anthropometric, clinical and biochemical parameters. %26lt;br%26gt;Results: Serum glutamic oxaloacetic transaminase (SGOT; p=0.027), log (erythrocyte sedimentation rate) (ESR; p=0.034) and homocysteine (p=0.041) were associated with NASH independently from gender, age and body mass index. When combined, the regression model provided R-2=0.563 (p=0.001) and area under the ROC curve=0.873 +/- 0.066 (p %26lt; 0.001). %26lt;br%26gt;Conclusion: This noninvasive marker, named HSENSI (acronym of homocysteine, SGOT, ESR, Nonalcoholic Steatohepatitis Index), consists of three low cost, easily measurable parameters and may accurately predict NASH.

• 出版日期2013-11
• 单位中国人民解放军空军总医院